argenx SE

ARGX ·Healthcare, Drug Manufacturers - General
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Assets
Cash & Equivalents $3.49B $1.50B $2.05B $800.7M $1.33B $1.22B $372.2M
Accounts Receivable $1.65B $904.5M $496.7M $275.7M $38.2M $7.0M $31.6M
Inventory $473.5M $407.2M $310.6M $228.4M $109.1M $25.2M —
Total Current Assets $6.90B $4.88B $4.12B $2.77B $2.54B $2.06B $1.54B
Property, Plant & Equipment $48.2M $43.5M $22.7M $16.2M — — —
Goodwill — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — — —
Total Assets $8.68B $6.20B $4.54B $3.13B $2.85B $2.28B $1.61B
Liabilities
Accounts Payable $1.27B $650.0M $414.0M $295.7M $293.4M $275.2M $95.8M
Total Current Liabilities $1.32B $669.9M $423.0M $302.3M $301.2M $328.5M $179.7M
Long-Term Debt — — — — — — —
Total Liabilities $1.36B $704.2M $445.0M $320.6M $316.1M $605.4M $429.8M
Stockholders' Equity
Retained Earnings $-279.8M $-1.57B $-2.40B $-2.11B $-1.40B $-991.9M $-383.5M
Total Stockholders' Equity $7.32B $5.50B $4.10B $2.81B $2.53B $1.67B $1.18B